Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ZW10 interacting kinetochore protein (ZWINT)
- Target
- ZWINT
- Molecular classification
- Kinetochore protein, Outer kinetochore KNL1 complex subunit, Structural protein, Other
01
Overview
ZW10 interacting kinetochore protein (ZWINT) is a structural component of the outer kinetochore KNL1 complex, playing an essential adaptor role in chromosome segregation during mitosis and meiosis. ZWINT is required for proper assembly and function of the spindle assembly checkpoint and ensures faithful kinetochore-microtubule interactions. The protein acts by recruiting the RZZ complex and mitotic checkpoint proteins to the kinetochore and is regulated by post-translational modifications such as phosphorylation by Aurora B kinase and targeted degradation by APC/C–Cdc20. ZWINT overexpression is associated with several cancers, where it contributes to tumor proliferation, invasiveness, and poor clinical outcomes, making it a candidate biomarker and possible therapeutic target in oncology. No drugs are currently known to interact directly with ZWINT, and its direct modulation remains experimental.
- Other names
- Zwint-1KNTC2APSIP30ZWINT1HZwint-1SNAP25 interacting protein of 30 kDaZW10 interactorouter kinetochore KNL1 complex subunit ZWINT
02
Mechanism of action
Not established for drugs (target not yet drugged in current literature) Theoretical mechanisms could include inhibition leading to mitotic arrest or apoptosis in cancer cells
03
Biological functions
Chromosome segregationSpindle assembly checkpoint signalingMitotic and meiotic cell cycle regulationMicrotubule-kinetochore interactionCell divisionCell proliferation
04
Disease associations
Cancer (notably glioblastoma, prostate cancer, cervical cancer, breast cancer)TumorigenesisMicrocephaly (genetic association)Other genomic instability disorders
05
Safety considerations
Potential risks include chromosome segregation defects, aneuploidy, unintended mitotic arrest, and toxicity in proliferating normal cells if therapeutically targeted
06
Interacting drugs
None reported in current databases or literature
07
Biomarkers
Overexpression is a potential biomarker for cancer prognosis and aggressiveness (e.g., glioblastoma, prostate, cervical, breast cancers)Potential biomarker for tumor proliferation and invasion
Beyond the preview
Go deeper on ZW10 interacting kinetochore protein (ZWINT).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZW10 interacting kinetochore protein (ZWINT).